Notice of Reduction of Tariffs on Patented Pharmaceuticals and Pharmaceutical Ingredients for Products of the United Kingdom Implemented by Presidential Proclamation 11020
What happened
This notice revises the tariff rate on patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United Kingdom. The tariff rate has been changed from 10 percent to zero percent. This action is in accordance with Proclamation 11020, titled "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States."
Why it matters
Reducing tariffs to zero could make patented pharmaceuticals and their ingredients imported from the United Kingdom cheaper in the United States. This change may impact the cost of certain medicines available to consumers and healthcare providers.
Who it affects
- ›United Kingdom pharmaceutical manufacturers
- ›United States pharmaceutical importers
- ›Consumers of patented pharmaceuticals
- ›Healthcare providers
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.